A validated risk stratification that incorporates MAGIC biomarkers predicts long term outcomes in pediatric patients with acute GVHD

Allogeneic hematopoietic cell transplantation (HCT) cures large numbers of children with malignant and non-malignant diseases but not all children who might benefit receive the procedure, despite advances in donor selection and supportive care1-3. A major barrier to greater use of allogeneic HCT is the risk for developing acute graft-versus-host disease (GVHD), which occurs in about one third of children and causes substantial morbidity and mortality4-7. Advances in GVHD management are particularly important for children who undergo transplant for non-malignant diseases that are curable by allogeneic HCT and for which the graft-vs-leukemia effect is not needed, such as bone marrow failure syndromes, hemoglobinopathies, and inborn errors of metabolism8-10.

Source: Biology of Blood and Marrow Transplantation - March 26, 2024 Category: Hematology Authors: Muna Qayed, Urvi Kapoor, Scott Gillespie, Adrianna Westbrook, Paibel Aguayo-Hiraldo, A. Francis Ayuk, Mina Aziz, Janna Baez, Hannah Choe, Zachariah DeFilipp, Aaron Etra, Stephan A. Grupp, Elizabeth Hexner, Ernst Holler, William J. Hogan, Steven Kowalyk, P Source Type: research